📰 Chas Schultz News
Page 6 - Chas Schultz News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Chas Schultz. Real-time updates on events, politics, business and more.
October 3, 2022
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer - read this article along with other careers information, tips and advice on BioSpace
August 12, 2022
12.08.2022 - Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s ...
July 12, 2022
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 12, 2022, the Compensation...
April 2, 2022
Late-breaking presentation of analysis of SCORED clinical trial data describes significant reduction in cardiovascular death, myocardial infarction and...
March 21, 2022
21.03.2022 - Late-breaking clinical trial presentation by Deepak L. Bhatt, M.D., M.P.H., will describe new analysis of rates of CV death, myocardial infarction and stroke in the SCORED trialTHE WOODLANDS, Texas, March 21, 2022 (GLOBE NEWSWIRE) - Lexicon ...
November 3, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
July 29, 2021
Replay International Dial-in Number: (404) 537-3406 Conference ID: 3687855 The dial-in replay will be available for 14 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and functi...
December 31, 2020
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in ... Lexicon Pharmaceuticals, Inc.December 31, 2020 GMT THE WOODLANDS, Texas, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for...